During the fourth quarter, sales climbed to $33.4 billion aided by a 14% increase in pharmacy sales in the US, especially in the Rite Aid stores. The top-line, however, slightly missed analysts’ forecast. Sales of Retail Pharmacy-International dropped 1.9%, while those of Pharmaceutical Wholesale rose 2.3% during the three-month period.
“We are making progress on our partnership strategy both in the U.S. and internationally, including our most recent announcements with LabCorp, Kroger and Alibaba, which will provide additional opportunities for future growth,” said Walgreens CEO Stefano Pessina.
Walgreens acquires pharmacy files from Fred’s for $165 million
In the whole of 2018, the management returned $6.8 billion to shareholders through stock repurchases and dividends. In fiscal 2019, adjusted earnings are expected to be in the range of $6.40 per share to $6.70 per share, at current exchange rates. At constant currency rates, earnings are seen rising between 7% and 12%.
After acquiring about 50% of the Rite Aid pharmacy chain a few years ago, Walgreens expanded its footprint in the healthcare services sector significantly. New developments such as the proposed acquisition of Aetna (AET) by CVS Health (CVS) and Amazon’s (AMZN) entry into pharmacy business are expected to intensify competition in the sector in the coming months.
Walgreens shares closed the previous trading session down 2% and dropped further in premarket trading Thursday after the earnings announcement.